These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37373190)

  • 1.
    Acharya S; Lumley AI; Zhang L; Vausort M; Devaux Y; On Behalf Of The Ncer-Pd Consortium
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular history and risk of idiopathic Parkinson's disease: a cross-sectional observational study.
    Acharya S; Lumley AI; Devaux Y;
    BMC Neurosci; 2024 Jul; 25(1):33. PubMed ID: 38977971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients.
    Santiago JA; Potashkin JA
    PLoS One; 2015; 10(11):e0142582. PubMed ID: 26566043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated Plasma microRNA-105-5p Level in Patients With Idiopathic Parkinson's Disease: A Potential Disease Biomarker.
    Yang Z; Li T; Cui Y; Li S; Cheng C; Shen B; Le W
    Front Neurosci; 2019; 13():218. PubMed ID: 30936821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease.
    Gaig C; Vilas D; Infante J; Sierra M; García-Gorostiaga I; Buongiorno M; Ezquerra M; Martí MJ; Valldeoriola F; Aguilar M; Calopa M; Hernandez-Vara J; Tolosa E
    PLoS One; 2014; 9(10):e108982. PubMed ID: 25330404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arterial spin labelling reveals prolonged arterial arrival time in idiopathic Parkinson's disease.
    Al-Bachari S; Parkes LM; Vidyasagar R; Hanby MF; Tharaken V; Leroi I; Emsley HC
    Neuroimage Clin; 2014; 6():1-8. PubMed ID: 25379411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Relationship Among Bone Mineral Density, Bone Biomarkers and Vitamin D Levels in Patients with Parkinson's Disease.
    Can NU; Alagöz AN
    Clin Lab; 2020 Aug; 66(8):. PubMed ID: 32776751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson's disease.
    Botta-Orfila T; Morató X; Compta Y; Lozano JJ; Falgàs N; Valldeoriola F; Pont-Sunyer C; Vilas D; Mengual L; Fernández M; Molinuevo JL; Antonell A; Martí MJ; Fernández-Santiago R; Ezquerra M
    J Neurosci Res; 2014 Aug; 92(8):1071-7. PubMed ID: 24648008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Characteristics of Parkinson's Disease Developed from Essential Tremor.
    Ryu DW; Lee SH; Oh YS; An JY; Park JW; Song IU; Lee KS; Kim JS
    J Parkinsons Dis; 2017; 7(2):369-376. PubMed ID: 28409750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neurofilament light chain in LRRK2 related Parkinson's disease: A five years follow-up.
    Nabizadeh F; Mohamadzadeh O; Hosseini H; Rasouli K; Afyouni NE
    J Clin Neurosci; 2023 Apr; 110():12-18. PubMed ID: 36780781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression.
    Niu M; Li Y; Li G; Zhou L; Luo N; Yao M; Kang W; Liu J
    Eur J Neurol; 2020 Jun; 27(6):967-974. PubMed ID: 32150777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body-First Subtype of Parkinson's Disease with Probable REM-Sleep Behavior Disorder Is Associated with Non-Motor Dominant Phenotype.
    Pavelka L; Rauschenberger A; Landoulsi Z; Pachchek S; Marques T; Gomes CPC; Glaab E; May P; Krüger R;
    J Parkinsons Dis; 2022; 12(8):2561-2573. PubMed ID: 36245388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
    Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
    Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
    Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased basal forebrain volumes could prevent cognitive decline in LRRK2 Parkinson's disease.
    Batzu L; Urso D; Grothe MJ; Veréb D; Chaudhuri KR; Pereira JB
    Neurobiol Dis; 2023 Jul; 183():106182. PubMed ID: 37286171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polygenic Risk Scores Validated in Patient-Derived Cells Stratify for Mitochondrial Subtypes of Parkinson's Disease.
    Arena G; Landoulsi Z; Grossmann D; Payne T; Vitali A; Delcambre S; Baron A; Antony P; Boussaad I; Bobbili DR; Sreelatha AAK; Pavelka L; J Diederich N; Klein C; Seibler P; Glaab E; Foltynie T; Bandmann O; Sharma M; Krüger R; May P; Grünewald A;
    Ann Neurol; 2024 Jul; 96(1):133-149. PubMed ID: 38767023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary data: Evaluation of serum Galectin-3 levels in patients with Idiopathic Parkinson's Disease.
    Yazar HO; Yazar T; Cihan M
    J Clin Neurosci; 2019 Dec; 70():164-168. PubMed ID: 31471077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of non-motor symptoms and their impact on the quality of life in patients with Parkinson's disease: a prospective descriptive case series.
    Gulunay A; Cakmakli GY; Yon MI; Ulusoy EK; Karakoc M
    Psychogeriatrics; 2020 Mar; 20(2):206-211. PubMed ID: 31782214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonmercaptalbumin as an oxidative stress marker in Parkinson's and PARK2 disease.
    Ueno SI; Hatano T; Okuzumi A; Saiki S; Oji Y; Mori A; Koinuma T; Fujimaki M; Takeshige-Amano H; Kondo A; Yoshikawa N; Nojiri T; Kurano M; Yasukawa K; Yatomi Y; Ikeda H; Hattori N
    Ann Clin Transl Neurol; 2020 Mar; 7(3):307-317. PubMed ID: 32059082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-syn and SNP rs356219 as a potential biomarker in blood for Parkinson's disease in Mexican Mestizos.
    Salas-Leal AC; Salas-Pacheco SM; Gavilán-Ceniceros JAP; Castellanos-Juárez FX; Méndez-Hernández EM; La Llave-León O; Camacho-Luis A; Quiñones-Canales G; Romero-Gutiérrez E; Arias-Carrión O; Salas-Pacheco JM; Sandoval-Carrillo AA
    Neurosci Lett; 2021 May; 754():135901. PubMed ID: 33865938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.